Literature DB >> 21658742

Frequency, phenotype, and genotype of minute gastrointestinal stromal tumors in the stomach: an autopsy study.

Simone Muenst1, Svenja Thies, Philip Went, Luigi Tornillo, Michel P Bihl, Stephan Dirnhofer.   

Abstract

Gastrointestinal stromal tumors are the most common mesenchymal tumors of the human digestive tract. Up to 85% of these tumors show somatic gain-of-function mutation of the receptor tyrosine kinase c-KIT gene. A recent study has shown a high frequency (22.5%) of minute gastrointestinal stromal tumors in stomachs examined during routine autopsies. The aims of our study were to confirm the previously reported incidence of gastric gastrointestinal stromal tumors in routine autopsies and to investigate their molecular alterations. Gastrointestinal stromal tumors were collected prospectively from 578 autopsies over an 18-month period. After recording the size and location of each lesion, representative tissue samples were processed for hematoxylin and eosin staining and immunohistochemically stained for CD117 and CD34. Microdissected DNA from all identified gastrointestinal stromal tumors was studied for c-KIT and platelet-derived growth factor receptor α mutations. We identified 17 gastrointestinal stromal tumors in 578 consecutive autopsies (2.9%) located in the gastric body (47%) and fundus (47%). One tumor location was not recorded. All tumors were immunohistochemically positive for CD117 and CD34. DNA analysis showed c-KIT mutations in 11 cases. One platelet-derived growth factor receptor α mutation was found. The incidence of gastric minute gastrointestinal stromal tumors (2.9%) is higher than the reported clinical incidence. All are benign tumors, and most, including minute tumors, contain c-KIT mutations. This finding highlights the fact that c-KIT mutations are an early event in the evolution of gastrointestinal stromal tumors but are not sufficient per se for clinically relevant disease.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21658742     DOI: 10.1016/j.humpath.2011.01.024

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  13 in total

1.  Clinicopathological features and prognosis of 276 cases of primary small (≤ 2 cm) gastric gastrointestinal stromal tumors: a multicenter data review.

Authors:  Zifeng Yang; Xingyu Feng; Peng Zhang; Tao Chen; Haibo Qiu; Zhiwei Zhou; Guoxin Li; Kai Xiong Tao; Yong Li
Journal:  Surg Endosc       Date:  2018-11-27       Impact factor: 4.584

Review 2.  Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy.

Authors:  Danielle Ferraro; John Zalcberg
Journal:  Ther Adv Med Oncol       Date:  2014-09       Impact factor: 8.168

Review 3.  Gastrointestinal stromal tumours: origin and molecular oncology.

Authors:  Christopher L Corless; Christine M Barnett; Michael C Heinrich
Journal:  Nat Rev Cancer       Date:  2011-11-17       Impact factor: 60.716

4.  Clinicopathological Outcomes and Prognosis of Elderly Patients (≥ 65 Years) with Gastric Gastrointestinal Stromal Tumors (GISTs) Undergoing Curative-Intent Resection: a Multicenter Data Review.

Authors:  Zifeng Yang; Xingyu Feng; Peng Zhang; Tao Chen; Haibo Qiu; Yongjian Zhou; Chunyan Du; Xiaonan Yin; Fang Pan; Guoliang Zheng; Xiufeng Liu; Changming Huang; Zhiwei Zhou; Guoxin Li; Kaixiong Tao; Yong Li
Journal:  J Gastrointest Surg       Date:  2018-10-15       Impact factor: 3.452

Review 5.  [Mesenchymal tumors and tumor-like lesions of the gastrointestinal tract: an overview].

Authors:  Abbas Agaimy
Journal:  Pathologe       Date:  2021-12-17       Impact factor: 1.011

Review 6.  Gastrointestinal stromal tumor - an evolving concept.

Authors:  Luigi Tornillo
Journal:  Front Med (Lausanne)       Date:  2014-11-11

Review 7.  Genetic progression in gastrointestinal stromal tumors: mechanisms and molecular interventions.

Authors:  Ke Li; Haibo Cheng; Zhang Li; Yuzhi Pang; Xiaona Jia; Feifei Xie; Guohong Hu; Qingping Cai; Yuexiang Wang
Journal:  Oncotarget       Date:  2017-03-08

8.  Which size is the best cutoff for primary small gastric gastrointestinal stromal tumor?

Authors:  Xingyu Feng; Zifeng Yang; Peng Zhang; Tao Chen; Haibo Qiu; Zhiwei Zhou; Guoxin Li; Kaixiong Tao; Hui Wang; Yong Li
Journal:  J Gastrointest Oncol       Date:  2020-04

9.  Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib.

Authors:  Heikki Joensuu; Jean-Yves Blay; Alessandro Comandone; Javier Martin-Broto; Elena Fumagalli; Giovanni Grignani; Xavier Garcia Del Muro; Antoine Adenis; Claudia Valverde; Antonio Lopez Pousa; Olivier Bouché; Antoine Italiano; Sebastian Bauer; Carlo Barone; Claudia Weiss; Stefania Crippa; Maura Camozzi; Ramon Castellana; Axel Le Cesne
Journal:  Br J Cancer       Date:  2017-08-29       Impact factor: 7.640

Review 10.  Current clinical management of gastrointestinal stromal tumor.

Authors:  Kazuya Akahoshi; Masafumi Oya; Tadashi Koga; Yuki Shiratsuchi
Journal:  World J Gastroenterol       Date:  2018-07-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.